The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials

INTRODUCTION: A great number of anti-inflammatory drugs have been suggested in the treatment of SARS-CoV-2 infection. Reparixin, a non-competitive allosteric inhibitor of the CXCL8 (IL-8) receptors C-X-C chemokine receptor type 1 (CXCR1) and C-X-C chemokine receptor type 2 (CXCR2), has already been...

Descripción completa

Detalles Bibliográficos
Autores principales: Landoni, Giovanni, Zangrillo, Alberto, Piersanti, Gioia, Scquizzato, Tommaso, Piemonti, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358031/
https://www.ncbi.nlm.nih.gov/pubmed/35958623
http://dx.doi.org/10.3389/fimmu.2022.932251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358031/
https://www.ncbi.nlm.nih.gov/pubmed/35958623
http://dx.doi.org/10.3389/fimmu.2022.932251

Ejemplares similares